Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin'... (linical efficacywith PCI-32765 in these ...)

Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

Date:4/13/2009

linical efficacy with PCI-32765 in these disease models," said Dr. Mark Genovese, Professor of Medicine and Co-Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center and member of Pharmacyclics' Scientific Advisory Board.

"Despite recent success with biologics in the treatment of B-cell NHL, there is still a large group of patients that do not respond to therapy or who experience recurrence," said Ranjana Advani, MD, Associate Professor, Stanford University Medical Center and principle investigator of the Phase 1 clinical trial. "A drug that could not only have an impact on this patient group, but also be delivered orally would represent a significant step forward in the treatment of this disease."

This Phase 1 study is evaluating the safety and pharmacokinetics of PCI-32765 in patients with refractory B-cell non-Hodgkin's lymphoma at Stanford University, MD Anderson Cancer Center and the University of Chicago using a 28-day dose-escalation design. The study is also utilizing a proprietary pharmacodynamic assay developed by Pharmacyclics to directly assess Btk drug occupancy. Preliminary results from the Phase I trial shows good patient tolerability under conditions of Btk-drug occupancy with potent bioactivity in targeted cell populations derived from the B-cell lymphoma patients.

Pharmacyclics Btk Presentations at AACR

Monday April 20, 2009

9:30 am - 1:00 pm; Minisymposium Novel Molecular Targets / Targeting Cell Death Pathways; Experimental and Molecular Therapeutics 12 Room 405-407, Colorado Convention Center 9:40am-9:55am

#1984 Btk is a Novel Therapeutic Target to Treat Large B-cell Lymphomas Ryan M. Young, Ashley Smith, Lee Honigberg, Yosef Refaeli. National Jewish Health, Denver, CO, Pharmacyclics, Inc., Sunnyvale, CA

Tuesday April 21, 2009

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
2. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
3. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
6. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
7. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
10. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
11. Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma

Post Your Comments:

(Date:5/22/2013)... 2013 Grifols, ein globales Unternehmen der ... , Spanien, präsentierte die Ergebnisse einer ... von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des ... ein Niveau anhebt, das innerhalb des für ... ist eine lebensbedrohliche, genetische Erkrankung, bei der ...

(Date:5/22/2013)... Israel , May 22, 2013 /PRNewswire/ ... leading developer and provider of microRNA-based molecular diagnostics, announces ... and Chief Executive Officer of Rosetta Genomics, will deliver ... taking place from June 3-6, 2013 in New York ... June 4 th at 2:00 p.m. Eastern time. ...

(Date:5/22/2013)... , May 22, 2013 Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ... http://wsw.com/webcast/marcum/mfs.v/ For more information and registration, ...

Breaking Medicine Technology:Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2 Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3 Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 2 Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference 3 Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2 Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3

[0] Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt [0] Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference [0] Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference

... June 21 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... treatments for human disease, presented clinical data and analysis from ... patients with type 2 diabetes mellitus at ENDO 2010 today. ... of increased total GLP-1 in both LX4211 treatment arms relative ...

... 21 Reportlinker.com announces that a new market research report is available ... Global Coronary ... , , ... , , ...

Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016

(Date:5/22/2013)... (PRWEB) May 22, 2013 Hosted by ... Cares free dental clinic provided more than $1.6 million ... May 18-19 in San Jose. , The California ... the clinic to provide free dental services and oral ... This is the third clinic held by CDA and ...

(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Anyone ... is something about feet that fungi seem to like. ... the fungal groups that live on your skin -- ... It,s no secret that the human body is ... fungi, both outside and inside. And it,s mainly a ...

(Date:5/22/2013)... 2013 Successful Therapy for Parents ... Psychotherapy in the Silver Lake community of Los ... as progression to existing Parents and Couples counseling ... parenting therapy has always been suggested, but now ... now specializes in all aspects of relationships ...

(Date:5/22/2013)... 22, 2013 According to a May 14, ... More Options for Breast Cancer Surgery,” modern medical technology has ... approach this disease in a whole new light. Since the ... now face breast cancer and mastectomies with greater ... “Before the introduction of plastic surgery to oncology, women had ...

(Date:5/22/2013)... Researchers in genomic health disparities from the University of ... School of Medicine have teamed up to hold the ... Health Disparities in Genomic Medicine." The theme of ... business and government to reduce these disparities. , Despite ... States, individuals within underserved groups continue to be more ...

Breaking Medicine News(10 mins):Health News:Two-day San Jose Dental Clinic Provides More Than $1.6 Million in Care 2 Health News:Scientists Map the Fungi on Your Feet 2 Health News:Scientists Map the Fungi on Your Feet 3 Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2 Health News:Breast Augmentation – New Option for Breast Cancer Surgeries 2 Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2

[0] Two-day San Jose Dental Clinic Provides More Than $1.6 Million in Care [0] Scientists Map the Fungi on Your Feet [0] Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children [0] Breast Augmentation – New Option for Breast Cancer Surgeries [0] Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine

... health system of southern Australian hospitals has been graded at ... surgery admissions //and waiting times. ,This rating has ... recorded the second highest number of beds per capita in ... for every 1000 in population. ,Health Minister Tony ...

... New South Wales in Australia have developed a "super ... diabetes//, heart disease, arthritis and cancer. The drug, Dz13, ... aging as well, the researchers claimed. ,Also diseases like ... in a paper published in the latest issue of ...

... Pharma today said it has recieved a tentative New ... product used for treating HIV-1 infection//. ... drug product containing Lamivudine, Zidovudine, Nevirapine tablets used in ... Bombay Stock Exchange., ,The three drugs would now ...

... have discovered a method to cease the blood supply to ... cancer//. This, if proved conclusively, will infuse a new lease ... a protein, discovered while conducting a research on fruits, is ... them naturally. , ,The researchers said “By blocking the ...

... members and villagers, a woman who lost her husband to AIDS ... Bihar home. ,Premila Devi, 40, from Tilaei village in ... just a few months after her husband Sunil Mahto died of ... members as well as villagers treated her after her husband's death," ...

... determination test kits to counter online threats to its skewed ... Home DNA gender testing kit' for $275 promising results within ... unborn girls in Punjab, Haryana and Delhi. ,"We ... Health Minister Ramesh Chander Dogra told a news channel Sunday. ...

Cached Medicine News:Health News:South Australian health System In The Bottom Of Rankings 2

South Australian health System In The Bottom Of Rankings "Super Drug" Targets Disease-Causing Gene Aurobindo Gets Tentative USFDA Approval For Its HIV-1 Drug Cessation of blood supply to cancer cells may curtail spread, novel research Ostracized AIDS Patient Commits Suicide in Bihar Punjab Plans of Banning Sex Determination Kit from US

... Quality EEG recording is assured even ... Neurofax has high performance, high sensitivity ... ECG rejection filter, shielded electrodes and a ... connection. Neurofax is a complete and ...

... MagPro is the high performance magnetic stimulator ... in medical research. , ,MagPro is able to ... precise studies of the field/nerve interface can be ... biphasic waveform and coil-current direction. , , , ...

... is a new top-line range of digital ... Atrial Fibrillation (AF). Because the T-series combines ... the treatment of AF is taken one ... the heart rhythm is monitored continuously and ...

... MAX Cooling Power, Deeper Lesions ... arrhythmias, including atrial flutter, Freezor MAX is ... catheter with an 8mm ablation tip was ... is connected to the same cryoconsole as ...

Medicine Products:

Neurofax EEG-9100 MagPro T-series (T70 DR, T60 DR, T20 SR )Freezor MAX